Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva, Zixu Wang, Jessica Lowney, Samantha Pazienza, Josie Montegaard, Victoria Patterson, Matthew Weinstock, Jennifer L. Crombie, Samuel Y. Ng, Austin I. Kim, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, Jon Arnason, David C. Fisher, Jennifer R. Brown